For the clinical specimens, Latil and colleagues [128] demonstrated detectable levels of ERα and ERβ transcripts in both normal and cancer tissues and they found downregulation of ERβ mRNA expression in one half of either localized or hormone-refractory tumors. This evidence concerns the gene ESR2 and cancer.